Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma



This study aims to determine the sensitivity, specificity and accuracy of epidermal growth factor receptor monoclonal antibody (EGFRmAb) modified poly(lactic acid-co-l-lysine) nanoparticles (PLA-PLL-EGFRmAb) NPs delivery system to EGFR positive cancer cells. In the study, a new PLA-PLL-EGFRmAb NPs was prepared. The cellular cytotoxicity, cellular uptake, and the targeted effect for hepatocellular carcinoma of PLA-PLL-EGFRmAb NPs were investigated. In vitro, the findings of Flow cytometry and Confocal Laser scanning Biological Microscopy showed that PLA-PLL-EGFRmAb NPs can bind to hepatocellular carcinoma cells and were uptaken effectively. In vivo in the SMMC-7721 xenograft mouse model, PLA-PLL-EGFRmAb NPs could target to the tumor effectively, which demonstrated a better targeting. These results showed that the PLA-PLL-EGFRmAb NPs have the potential to be used as a target delivery carrier for tumor therapies.


Epidermal Growth Factor Receptor Phosphate Buffer Solution Tumor Bearing Mouse Methylene Dichloride Growth Factor Receptor Monoclonal Antibody 



This research was supported by National 973 Basic Research Program of China (No. 20108529902), National 863 Research Program of China (No. 2007AA021203), National Natural Science Foundation of China (No. 50673058), Shanghai Municipal Public Health Bureau (No. 2008Y088) and Nano-Science and Technology from Science and Technology Commission of Shanghai Municipality (No. 0852nm05800).


  1. 1.
    Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev. 2008;60:1037–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007;59:718–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86:215–23.CrossRefPubMedGoogle Scholar
  4. 4.
    Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57–64.PubMedGoogle Scholar
  5. 5.
    Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818–22.CrossRefPubMedADSGoogle Scholar
  6. 6.
    Stayton PS, Hoffman AS, Murthy N, Lackey C, Cheung C, Tan P, et al. Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. J Control Release. 2000;65:203–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J Drug Target. 2004;12:461–71.CrossRefPubMedGoogle Scholar
  8. 8.
    Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem. 2008;19:2321–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Mitra A, Coleman T, Borgman M, Nan A, Ghandehari H, Line BR. Polymeric conjugates of mono- and bi-cyclic alphavbeta3 binding peptides for tumor targeting. J Control Release. 2006;114:175–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005;107:262−75.CrossRefPubMedGoogle Scholar
  11. 11.
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.CrossRefPubMedGoogle Scholar
  12. 12.
    Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer. Perspectives for targeted therapies. Lung Cancer. 2003;41(suppl 1):S29–42.CrossRefPubMedGoogle Scholar
  13. 13.
    Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EW, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res. 2002;107:247–58.PubMedGoogle Scholar
  14. 14.
    Di-Lorenzo G, Bianco R, Tortora G, Ciardiello F. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer. 2003;2:50−7.Google Scholar
  15. 15.
    Meert AP, Verdebout JM, Martin B, Ninane V, Feoli F, Sculier JP. Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions. Eur Respir J. 2003;21:611–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger D, et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res. 2002;8:734–44.PubMedGoogle Scholar
  17. 17.
    Selvaggi G, Novello S, Torri V, Leonardo E, De Giuli P, Borasio P, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol. 2004;15:28–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Sorkin A. Internalization of the epidermal growth factor receptor: role in signalling. Biochem Soc Trans. 2001;29:480–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou Y, Drummond DC, Zou H, Hayes ME, Adams GP, Kirpotin DB, et al. Impact of singlechain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptorexpressing tumor cells. J Mol Biol. 2007;371:934–47.CrossRefPubMedGoogle Scholar
  20. 20.
    Gao HP, Jiang H, Wang HM, Li ZH. Preparation and identification of anti-EGFRvIII/EGFR monoclonal antibody 9B9. Chin J Cancer Biother. 2009;16:391−5.Google Scholar
  21. 21.
    Yu H, Guo XJ, Qi XL, Liu PF, Shen XY, Duan YR. Synthesis and characterization of arginine-glycine-aspartic peptides conjugated poly (lactic acid-co-l-lysine) diblock copolymer. J Mater Sci Mater Med. 2008;19:1275–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Duan YR, Xu S, Wang Q, Liu J, Zhang ZR. Optimization of preparation of DHAQ-loaded PEG-PLGA-PEG nanoparticles using central composite design. J Mater Sci Mater Med. 2006;17:559–63.CrossRefPubMedGoogle Scholar
  23. 23.
    Eliyahu H, Barenholz Y, Domb AJ. Polymers for DNA delivery. Molecules. 2005;10:34–64.CrossRefPubMedGoogle Scholar
  24. 24.
    Veiseh O, Kievit FM, Gunn JW, Ratner BD, Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials. 2009;30:649–57.CrossRefPubMedGoogle Scholar
  25. 25.
    Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm. 2008;70:718–25.CrossRefPubMedGoogle Scholar
  26. 26.
    Pan J, Feng SS. Targeting and imaging cancer cells by folate decorated, “quantum dots loaded nanoparticles of biodegradable polymers”. Biomaterials. 2009;30:1176–83.CrossRefPubMedGoogle Scholar
  27. 27.
    Chatterjee DK, Fong LS, Zhang Y. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008;60:1627–37.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.State Key Lab for Modification of Chemical Fibers and Polymer Materials, College of Materials Science and EngineeringDonghua UniversityShanghaiPeople’s Republic of China
  2. 2.National Laboratory for Oncogenes and Related GenesCancer Institute of Shanghai Jiao Tong UniversityShanghaiPeople’s Republic of China
  3. 3.Cancer Institute of Shanghai Jiao Tong UniversityShanghaiPeople’s Republic of China

Personalised recommendations